Protagonist Therapeutics Files 8-K/A Amendment

Ticker: PTGX · Form: 8-K/A · Filed: Mar 11, 2025 · CIK: 1377121

Sentiment: neutral

Topics: amendment, financial-statements, exhibits

TL;DR

Protagonist Therapeutics filed an amendment to its 8-K, updating financial statements and exhibits as of March 8, 2025.

AI Summary

Protagonist Therapeutics, Inc. filed an 8-K/A on March 11, 2025, to amend a previous filing. The amendment pertains to financial statements and exhibits, with the earliest event reported being March 8, 2025. No specific financial details or events triggering the amendment were detailed in the provided text.

Why It Matters

This filing indicates an update or correction to a previous report, which could be significant for investors monitoring the company's financial disclosures and regulatory compliance.

Risk Assessment

Risk Level: low — The filing is an amendment to a previous report, indicating a procedural update rather than a new material event.

Key Players & Entities

FAQ

What specific financial statements or exhibits are being amended in this 8-K/A filing?

The provided text states the amendment pertains to 'Financial Statements and Exhibits' but does not specify which ones.

What was the original filing date of the report being amended?

The filing date of the original report is not specified in the provided text, only that this is an amendment.

What is the primary reason for Protagonist Therapeutics filing this 8-K/A?

The filing is an amendment to a previous report, specifically concerning financial statements and exhibits, with the earliest event date being March 8, 2025.

What is Protagonist Therapeutics, Inc.'s standard industrial classification?

The company's standard industrial classification is 'PHARMACEUTICAL PREPARATIONS [2834]'.

Where is Protagonist Therapeutics, Inc. headquartered?

The company's business address is listed as 7707 Gateway Blvd., Suite 140, Newark, CA 94560-1160.

Filing Details

This Form 8-K/A (Form 8-K/A) was filed with the SEC on March 11, 2025 regarding Protagonist Therapeutics, Inc (PTGX).

View full filing on EDGAR

View Full Filing

View this 8-K/A filing on SEC EDGAR

View on Read The Filing